A major feature added in 3.0 is a user-selectable series of preset filters. These allow users to select drug–gene interactions that align with some of the most common search use cases. While it was possible for a user to filter on some of the following attributes in 2.0, these concepts have now been structured as stand-alone filters that can help focus a user's search results with a single click. The filters currently include FDA-approved drugs, anti-neoplastic drugs, immunotherapy drugs, clinically actionable genes, genes included in the druggable genome definition and drug resistant genes. FDA approval status is extracted from ChEMBL v23 (current as of this writing) (14). Anti-neoplastic drugs are defined by inclusion in an anti-neoplastic drug–gene interaction source (e.g. My Cancer Genome), or as a drug with an anti-neoplastic attribute from its constituent source. Immunotherapy drugs are defined as any drug with an attribute of ‘immunosuppressive agent’, ‘immunomodulatory agent’ or ‘immunostimulant’. Clinically actionable genes are genes that constitute the DGIdb ‘clinically actionable’ gene category, and by definition is used to inform clinical action (e.g. the Foundation One diagnostic gene
